Industry Newsoncologybiotechmerckacquisitions
Merck Strengthens Pipeline Through Cidara Acquisition
5.0
Merck announced on November 14 it will acquire Cidara Therapeutics for about $9.2 billion and on November 24 Wells Fargo upgraded Merck to Overweight, raising its price target to $125 from $90. Management estimates the 20-drug late-stage pipeline could generate up to $50 billion at peak by the mid-2030s; Merck also raised its quarterly dividend 4.9% to $0.85 on November 18.
Key Points
- 1Announces $9.2 billion Cidara acquisition and Wells Fargo upgrade to Overweight with $125 target.
- 2Signals pipeline momentum and expects multiple readouts during a catalyst-rich 12–18 month period.
- 3Impacts valuation and risk ahead of Keytruda patent loss; peak pipeline revenue could reach $50 billion.
Scoring Rationale
Moderate corporate milestone with acquisition and upgrades; limited AI/ML relevance reduces technical impact for data professionals.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
